AllSci News
Candel Therapeutics signs royalty deal, holds public offering ahead of prostate cancer approval
US-based Candel Therapeutics (Nasdaq: CADL) is preparing for the prospective approval of lead pipeline candidate aglatimagene besadenovec (CAN-2409) by announcing both a…
J&J pauses enrollment in Phase IIb for AC Immune-sourced Alzheimer’s vaccine
Switzerland-based AC Immune SA revealed in an SEC announcement that partner Johnson & Johnson (J&J) has temporarily halted enrollment in the Phase…
Merck reports positive Phase III SMART data for Enflonsia in second RSV season
Merck & Co., (NYSE: MRK) announced positive second-season findings from the global Phase III SMART study evaluating Enflonsia (clesrovimab) in infants and…
BriaCell transfers soluble CD80 cancer license to subsidiary BriaPro
BriaCell Therapeutics Corp. (Nasdaq: BCTX; TSX: BCT), a clinical-stage immunotherapy company headquartered in West Vancouver, British Columbia, announced a definitive asset purchase…
Aprea Therapeutics posts early data confirmation of WEE1 inhibitor’s potential
Pennsylvania-based Aprea Therapeutics (Nasdaq: APRE) announced preliminary data from the ongoing Phase I ACESOT-1051 trial showing a second unconfirmed partial response for…
Korsana Bio emerges from stealth with USD 175m to advance THETA shuttle antibody for Alzheimer’s
Korsana Biosciences, a Waltham, Massachusetts-based biotechnology company focused on neurodegenerative diseases, issued a press release announcing it has emerged from stealth with…
Merck turns to Mayo Clinic for AI-enabled research support
Merck & Co., Inc. and Mayo Clinic announced a multi-year research and development collaboration to utilize artificial intelligence (AI) and multimodal clinical…
GSK and ViiV post data supporting long-acting HIV drug Cabenuva’s benefits over daily pills
UK-based ViiV Healthcare and GSK announced positive final data from the Phase III LATITUDE trial evaluating Cabenuva (cabotegravir and rilpivirine) in individuals…
Moderna’s flu vaccine filing accepted for FDA review following regulatory about-face
The US FDA has belatedly accepted the Biologics License Application (BLA) for Moderna’s investigational seasonal influenza vaccine, mRNA-1010, for review. The company…
Novartis reports Phase III success for remibrutinib in chronic inducible urticaria
Novartis announced positive results from its Phase III program evaluating remibrutinib in patients with chronic inducible urticaria (CIndU), with the oral Bruton’s…
Lilly’s Zepbound shows combo promise with Taltz in psoriasis
Eli Lilly and Co., announced positive results from the Phase IIIb TOGETHER-PsO study evaluating the co-administration of the IL-17A inhibitor Taltz (ixekizumab)…
Henlius pushes tetra-specific T-cell engager into the clinic for SCLC, NEC
Shanghai Henlius Biotech has registered a first-in-human Phase I clinical trial evaluating pipeline candidate HLX3901 in adults with advanced small cell lung…
CSL and Eli Lilly enter USD 100m licensing agreement for clazakizumab
Australia-based CSL Ltd, announced an exclusive licensing agreement with Indianapolis, US-based Eli Lilly and Co., for the development and commercialization of clazakizumab.…
Nektar Therapeutics partners with UCSF to explore TNFR2 agonism against multiple sclerosis
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company headquartered in San Francisco, announced an academic research collaboration with the University of California,…
J&J wins FDA nod for subcutaneous Rybrevant in NSCLC
The FDA approved a simplified once-monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) in combination with Lazcluze (lazertinib) for first-line EGFR-mutated advanced NSCLC.
The AllSci Brief
Free, systematic R&D and deal news. Daily.